Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid

Leuk Lymphoma. 2013 Jul;54(7):1557-9. doi: 10.3109/10428194.2012.745933. Epub 2012 Dec 22.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Blast Crisis*
  • Brain / pathology
  • Central Nervous System / pathology*
  • Dasatinib
  • Genes, abl
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Magnetic Resonance Imaging
  • Male
  • Mutation
  • Neoplasm Recurrence, Local*
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / therapeutic use
  • Remission Induction
  • Thiazoles / pharmacokinetics
  • Thiazoles / therapeutic use

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Dasatinib